On January 17, 2023, Reuters released that President Joe Biden is currently pushing for a judge to reject a request from anti-abortionists who are urging for the withdrawal of federal approval over the drug Mifepristone. Mifeprex (the generic term) is a drug used to terminate early term pregnancies in women, and anti-abortion lobbyist claim that the drug poses a threat to women.

Attorneys for the FDA had this to say about the complaint: "The public interest would be dramatically harmed by effectively withdrawing from the marketplace a safe and effective drug that has lawfully been on the market for twenty-two years."

The drug in question, Mifepristone, is being sold under the generic name Mifeprex. The FDA announced that this will be available to the public starting January 3, 2023. The drug is used to terminate early term pregnancies (within the first 10 weeks).

This suit is receiving significant attention, likely because of the groundbreaking decision released by the Supreme Court in 2022, essentially overturning Roe v. Wade which stood strong since 1973. The landmark decision allowed women the opportunity for body autonomy, and the majority of the nation was heartbroken at the Dobbs decision in 2022.

In the filing, anti-abortionists like Alliance for Hippocratic Medicine and the American Association of Pro-Life Obstetricians and Gynecologists, claim that the drug is dangerous to the women who take it. They also submitted declarations from abortion providers directly who allegedly state that it would have to get rid of 17 of the 18 abortion service providers if Mifepristone becomes banned.

In response, the FDA states that there is no basis for the anti-abortion groups to question the FDA's judgement and determination that the drug in question is safe when used as directed. The FDA also states that banning the drug would increase the number of later-term and surgical abortions in patients.

The case is ongoing. Updates will be provided.